## ACAD: ACADIA Pharmaceuticals Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.7% in lower entry zone (4.0-10.0%), top 10% cross-sectional ranking. Short-term MRS_5 (2.2%) confirms momentum alignment. Momentum building (+0.6% 5-day). Outperforming sector by 7.0%.

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($24.10)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Mizuho | $29 | $24 | +21% |
| 2025-11-17 | JP Morgan | $31 | $33 | -6% |
| 2025-11-06 | RBC Capital | $32 | $34 | -6% |
| 2025-11-06 | Needham | $29 | $28 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Mizuho | main | Neutral |
| 2025-11-17 | JP Morgan | main | Overweight |
| 2025-11-06 | RBC Capital | main | Outperform |
| 2025-11-06 | Needham | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.00M) |
| Sells | 3 ($1.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 4 |

**Top Holders:**
- Baker Bros. Advisors: 25.4% (0.0%)
- Blackrock Inc.: 12.0% (-1.9%)
- Vanguard Group Inc: 9.0% (-0.6%)
- State Street Corpora: 4.3% (+17.4%)
- RTW Investments LP: 4.2% (-20.6%)

### Key Risks

1. Elevated short interest (8.0%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Quality metrics strong (ROE 35%, margin 25%). Balance sheet: strong liquidity (3.0x), low leverage (D/E 0.45). Insider selling cluster ($1.0M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.7B |
| Beta | 0.67 |
| 52W Range | $13.40 - $28.35 |
| Short Interest | 8.0% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.42 |
| Forward P/E | 32.1 |
| Current P/E | 31.8 |
| YoY Growth | -1.2% |
| EPS Direction | RISING |

### Technicals

MRS_20 improving modestly (+0.6% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 90th percentile. MRS_5 at 2.2% confirms short-term momentum alignment. AM_20 at 8.8% shows strong absolute momentum above own 20MA. Outperforming sector by 7.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +STN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.73% (CS: 90) | Strong |
| RSI_14 | 69.4 | Neutral |
| MACD Histogram | 0.20 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.155x | Above |
| vs SMA200 | 1.232x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $25.88
- **Stop Loss:** $24.10 (6.9% risk)
- **Target:** $28.55 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 533
- **Position Value:** $13,794.04
- **Portfolio %:** 13.79%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderately constructive conditions. Fed dovish pivot expectations from weak jobs data and declining VIX suggest improving risk appetite, though narrow breadth at 51% indicates selective participation. Focus on quality sectors benefiting from rate cut expectations.*

### Earnings

**Next:** 2026-02-25 (Est: $0.14)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.15 | $0.42 | +189.0% |
| 2025Q2 | $0.14 | $0.16 | +15.3% |
| 2025Q1 | $0.11 | $0.11 | +4.5% |
| 2024Q4 | $0.22 | $0.86 | +292.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*